Patents by Inventor Elias Castanas
Elias Castanas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230101903Abstract: The present invention relates to compounds of Formula (I) and compositions containing one or more compounds of Formula (I). The compounds and compositions are useful as anti-viral agents and may be used in the treatment or prevention of diseases caused by ribonucleic acid (RNA) viruses.Type: ApplicationFiled: February 11, 2021Publication date: March 30, 2023Inventors: Elias CASTANAS, George SOURVINOS, Marilena KAMPA, Christos LIONIS, Stergios PIRINTSOS, Athanasios PANAGIOTOPOULOS, Melpomeni TSELIOU
-
Patent number: 9777037Abstract: The present invention relates to novel neurosteroid derivatives with anti-apoptotic, neuroprotective and neurogenic properties that act on the nervous system as well as methods for making the same and their applications in the treatment and/or prevention or amelioration of neurodegenerative diseases related to neuronal apoptosis or neuronal injury, or conditions related to or resulting from apoptosis, including but not limited to Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis and amyotrophic lateral sclerosis (ALS), retinal degeneration and detachment, peripheral neuropathy caused by genetic abnormalities, diabetes, polio, herpes, AIDS and chemotherapy, brain trauma, or ischemia and stroke. The active compounds are represented by Formula (I): wherein R1, R2, R3, R4, R5, R6, R7, A, B, X, Y and Z are defined in the description of the invention. The present invention also includes compositions which comprise one or more of the compounds of Formula (I).Type: GrantFiled: June 17, 2008Date of Patent: October 3, 2017Assignee: BIONATURE E. A. LTD.Inventors: Achilleas Gravanis, Theodora Calogeropoulou, Elias Castanas, Andreas Margioris, Ioannis Charalambopoulos, Nikolaos Avlonitis, Vassilios Minas, Vasileia-Ismini Alexaki, Christos Tsatsanis, Michael N. Alexis, Eumorphia Remboutsika, Varvara Vergou, Constantinos Neophytou
-
Publication number: 20130224285Abstract: The present invention presents new insights in the mechanism of action of the estrogen receptor alpha in breast cancer cells and provides means and tools for modulating said mechanisms of action, thereby influencing the proliferation of estrogen-positive cells such as cancer cells.Type: ApplicationFiled: October 13, 2011Publication date: August 29, 2013Applicants: Universite Libre de Buxelles, UNIVERSITE PIERRE ET MARIE CURIE - UPMC, CNRS, UNIVERSITY OF CRETE - SCHOOL OF MEDICINEInventors: Dominique Gallo, Guy LeClercq, Iman Haddad, Joelle Vinh, Elias Castanas, Marilena Kampa, Vasiliki Pelekanou, Yves Jacquot
-
Publication number: 20100234335Abstract: The present invention relates to novel neurosteroid derivatives with anti-apoptotic, neuroprotective and neurogenic properties that act on the nervous system as well as methods for making the same and their applications in the treatment and/or prevention or amelioration of neurodegenerative diseases related to neuronal apoptosis or neuronal injury, or conditions related to or resulting from apoptosis, including but not limited to Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis and amyotrophic lateral sclerosis (ALS), retinal degeneration and detachment, peripheral neuropathy caused by genetic abnormalities, diabetes, polio, herpes, AIDS and chemotherapy, brain trauma, or ischemia and stroke. The active compounds are represented by Formula (I): wherein R1, R2, R3, R4, R5, R6, R7, A, B, X, Y and Z are defined in the description of the invention. The present invention also includes compositions which comprise one or more of the compounds of Formula (I).Type: ApplicationFiled: June 17, 2008Publication date: September 16, 2010Applicant: BIONATURE E. A. LTD.Inventors: Achilleas Gravanis, Theodora Calogeropoulou, Elias Castanas, Andreas Margioris, Ioannis Charalambopoulos, Nikolaos Avlonitis, Vassilios Minas, Vasileia-Ismini Alexaki, Christos Tsatsanis, Michael N. Alexis, Eumorphia Remboutsika, Varvara Vergou, Constantinos Neophytou
-
Publication number: 20100086542Abstract: The present invention relates to the use of membrane steroid receptor agonists as potentiators of the action of erythropoietin (EPO). The present invention also relates to the combined use of membrane steroid receptor agonists and erythropoietin to control apoptosis, proliferation, differentiation, migration and regeneration of cells, in different organs and tissues. Compositions comprising (i) a membrane steroid receptor agonist and (ii) erythropoietin are also provided, as are kits comprising (i) a membrane steroid receptor agonist and (ii) erythropoietin.Type: ApplicationFiled: November 27, 2007Publication date: April 8, 2010Applicant: BIONATURE E.A. LTD.Inventors: Elias CASTANAS, Marilena KAMPA, Vassiliki PELEKANOU
-
Patent number: 7495115Abstract: Conjugates comprising one or more steroids conjugated with one or more mammalian proteins are disclosed. The conjugates are useful for diagnosis or treatment of solid cancer and haematological malignancies. Further the conjugates exhibits a synergistic action together with a cytoskeleton acting drug such as Taxol®, which enable the treatment of cancers that otherwise would be non responsive to Taxol®.Type: GrantFiled: July 14, 2003Date of Patent: February 24, 2009Assignee: Bionature E.A., Ltd.Inventor: Elias Castanas
-
Publication number: 20080267875Abstract: Conjugates comprising one or more steroids conjugated with one or more mammalian proteins are disclosed. The conjugates are useful for diagnosis or treatment of solid cancer aid haematological malignancies. Further the conjugates exhibits a synergistic action together with a cytoskeleton acting drug such as Taxol®, which enable the treatment of cancers that otherwise would be non responsive to Taxol®.Type: ApplicationFiled: March 28, 2008Publication date: October 30, 2008Applicant: BIONATURE E.A. LIMITEDInventor: Elias Castanas
-
Publication number: 20080227853Abstract: Disclosed is a method of treating or preventing a disorder influenced by the action of a membrane androgen receptor, wherein a patient suffering or expected of suffering of such disorder is administered in pharmaceutically effective amounts an agonist of the membrane androgen receptor, said agonist being selected among the group consisting of natural, unnatural, oligorimerised or rearranged catechin, epicatechin, and derivatives thereof. The disease being treated or prevented may be cancer.Type: ApplicationFiled: March 13, 2007Publication date: September 18, 2008Applicant: BIONATURE E. A. LIMITEDInventor: Elias Castanas
-
Publication number: 20080199549Abstract: Disclosed is method of treating or preventing an inflammatory condition, comprising administering to a person in need thereof an amount of a product derived from the plant Pistachia lentiscus var. chia effective to treat or prevent the inflammatory condition. In a preferred aspect the product is a dilution of the oily steam distillate of the resin. Also disclosed is a pharmaceutical composition comprising the product derived from the plant Pistachia lentiscus var. chia in a dilution of 10?5 or less.Type: ApplicationFiled: February 16, 2007Publication date: August 21, 2008Applicant: BIONATURE E. A. LIMITEDInventor: Elias Castanas
-
Patent number: 7358379Abstract: Conjugates comprising one or more steroids conjugated with one or more mammalian proteins are disclosed. The conjugates are useful for diagnosis or treatment of solid cancer and hematological malignancies. Further the conjugates exhibit a synergistic action together with a cytoskeleton-acting drug such as Taxol®, which enable the treatment of cancers that otherwise would be non-responsive to Taxol®.Type: GrantFiled: April 4, 2006Date of Patent: April 15, 2008Assignee: Bionature E.A. LimitedInventor: Elias Castanas
-
Publication number: 20060178295Abstract: Conjugates comprising one or more steroids conjugated with one or more mammalian proteins are disclosed. The conjugates are useful for diagnosis or treatment of solid cancer and hematological malignancies. Further the conjugates exhibit a synergistic action together with a cytoskeleton-acting drug such as Taxol®, which enable the treatment of cancers that otherwise would be non-responsive to Taxol®.Type: ApplicationFiled: April 4, 2006Publication date: August 10, 2006Inventor: Elias Castanas
-
Publication number: 20050245442Abstract: Conjugates comprising one or more steroids conjugated with one or more mammalian proteins are disclosed. The conjugates are useful for diagnosis or treatment of solid cancer and haematological malignancies. Further the conjugates exhibits a synergistic action together with a cytoskeleton acting drug such as Taxol®, which enable the treatment of cancers that otherwise would be non responsive to Taxol®.Type: ApplicationFiled: July 14, 2003Publication date: November 3, 2005Inventor: Elias Castanas